Parathyroid Hormone Kinetics During CRRT

Trends in Parathyroid Hormone Plasma Concentration in Multi-organ Failure Critically Ill Patients Undergoing Regional Citrate Anticoagulation Continuous Renal Replacement Therapies - Prospective Observational Study.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03873675

Enrollment

Registered

2019-03-13

Start date

2019-05-06

Completion date

2020-11-01

Last updated

2022-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Circulatory Failure, Critical Illness, Multi Organ Failure, Renal Failure, Respiratory Failure

Keywords

acute kidney injury, parathyroid hormone, continuous renal replacement therapy, citrate anticoagulation, intensive care

Brief summary

The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation continuous renal replacement therapy.

Interventions

DIAGNOSTIC_TESTparathyroid hormone

10-20ml blood samples taken from the arterial catheter every 12 hours to obtain parathyroid hormone serum concentration. 6-8 samples per patient

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute respiratory failure * Acute circulatory failure * acute kidney injury treated with regional citrate anticoagulation continuous renal replacement therapy by means of continuous veno-venous hemodiafiltration (CVVHDF * continuous renal replacement therapy started no later than 48 hours after admission * SOFA score 5 or more

Exclusion criteria

* age less than 18 years * acute liver failure * hypercalcemia at admission (total calcium plasma level \> 10.6 mg/dL; total ionized calcium plasma level \> 1.35 mmol/L * parathyroid glands disease * end stage renal disease * therapeutic plasma exchange * extracorporeal membrane oxygenation * unfavorable outcome (death) predicted within 72 hours (as assessed by investigator) * lack of relatives consent

Design outcomes

Primary

Measure	Time frame	Description
The change in parathyroid hormone serum concentration during regional citrate anticoagulation continuous renal replacement therapy (CRRT) in the acute phase of critical illness.	96 hours	The first parathyroid hormone serum level will be measured before the start of CRRT (the zero point) Next measurements will be performed every 12 hours. Minimal number of measurements - 6, maximal - 8 per patient.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026